Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / Hanash 3 marker panel for Lung Cancer

Hanash 3 marker panel for Lung Cancer



QA State: Accepted
Short Name:
HGNC Name:

The EDRN validation study ("Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques") presents evidence for the occurrence in lung cancer sera of autoantibodies to annexin 1, 14-3-3 theta and LAMR1, which precede the onset of symptoms and diagnosis. The combined AUC for these three antigens in CARET pre-clinical lung cancer sera vs. matched controls was 0.73. While autoantibodies to various cancer antigens have been reported in newly diagnosed lung cancer patient sera, an important aspect of this study is testing for occurrence of autoantibodies in pre-diagnostic sera and demonstration of significant autoantibody reactivity against LAMR1, annexin 1 and 14-3-3 theta.

Panel Details


The following organs have data associated with this biomarker…



Phase: Three
QA State: Under Review


This study provides evidence for a predictive effect, in pre-diagnostic lung cancer sera, of a 3-biomarker panel for lung cancer. The panel is comprised of three antigens, annexin 1, LAMR1 and 14-3-3 theta.

Supporting Study Data

The following studies/protocols provide evidence supporting Hanash 3 marker panel for Lung Cancer indications for the Lung…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.


No associated studies or protocols found.


No associated resources found.